tbuckley/cabot-search huggingface dataset:
Renal cell cancer (RCC): Use of metformin in the setting of renal impairment.
Authors: Nwabugwu Ochuwa, Kevin Finkel, Fangqian Ouyang, Robert J. Amato
Journal: Journal of Clinical Oncology (2013)

e15551 Background: Metformin is a biguanide that is widely used to treat type-2 diabetes and prediabetic syndromes. It has been found to inhibit RCC cell proliferation through activation of AMP-activated protein kinase (AMPK) and downstream inhibition of mammalian target of rapamycin (mTOR). Metformin is associated with potentially life threatening lactic acidosis (LA), but a clear link has not been established. We evaluated the occurrence of lactic acidosis in metformin-treated RCC patients with renal impairment. Methods: A retrospective study of 65 RCC patients treated with 250 to 2000 mg of metformin daily was conducted. Demographic data including age, gender, and ethnic background were collected. Data were collected on median metformin dose, eGFR, dialysis status, lactic acid, BUN, Na, K, Cl, and CO2 values. Results: Median metformin dose was 1000 mg daily in each group. Fifteen patients (23%) had elevated lactic acid &gt;4. The mean eGFR for patients with elevated lactic acid of &gt;4 vs. &lt;4is comparable (p=0.98). The two populations were significantly different at the BUN baseline level: patients with lactic acids &gt;4 have statistically significant smaller median baseline BUN level (median of 19.0 vs. 19.5; Wilcoxon two-sample p=0.03). Moreover, there is a marginally significant difference in age between these 2 groups (Mean of 58 vs. 62.8, Student's t-test p=0.07). Conclusions: Regardlessof lactic acid elevation, patients did not experience lactic acidosis. Complete data will be presented. [Table: see text]
CORONARY CALCIUM CHARACTERISTICS AS PREDICTORS OF MAJOR ADVERSE CARDIAC EVENTS IN SYMPTOMATIC PATIENTS: INSIGHTS FROM THE CORE320 MULTINATIONAL STUDY
Authors: Mallory Lo-Kioeng-Shioe, Andrea Vavere, Armin Arbab-Zadeh, Joanne Schuijf, Carlos Rochitte, Marcus Chen, Matthias Rief, Klaus Kofoed, Melvin Clouse, Arthur Scholte, Julie Miller, Aisha Betoko, Michael Blaha, Christopher Cox, Jaap W. Deckers, Joao Lima
Journal: Journal of the American College of Cardiology (2017)
Phase II trial of metformin and paclitaxel for patients with gemcitabine-refractory advanced adenocarcinoma of the pancreas.
Authors: Anezka Carvalho Rubin De Celis Ferrari, Tulio Eduardo Flesch Pfiffer, Alexandra Khichfy Alex, Daniela R. Nebuloni, Allyne Q. Carneiro, Fernanda Cunha Capareli, Luiz Antonio Senna Leite, Maria Ignez Freitas Melro Braghiroli, Juliana Lobo, Paulo Marcelo Hoff, Rachel Pimenta Riechelmann
Journal: Journal of Clinical Oncology (2014)

e15196 Background: Currently, there is no standard treatment for patients whose tumors progressed after 1st line gemcitabine-based regimens for pancreatic adenocarcinoma (PAC). Many pre-clinical studies have shown that metformin alone, or combined with paclitaxel, may have antitumor activity on PAC. We tested the combination of paclitaxel and metformin for patients with gemcitabine-refractory PAC. Methods: Uncontrolled phase II trial, based on a 2–stage Simon design, of metformin and paclitaxel for patients with locally advanced or metastatic PAC, ECOG 0-2, whose disease progressed on 1st line treatment with a gemcitabine-based regimen. The primary endpoint was disease control rate at 8 weeks (no progression) as per RECIST 1.1. The first stage should enroll 23 patients; if ≥ 12 patients (50%) reached the primary outcome, the study would enroll a total of 37. Patients received paclitaxel 80 mg/m2every 28 days, and metformin 850mg PO TID continuously until progression or intolerance. Results: Twenty patients were enrolled from July 2011 to January 2014. Nineteen patients were evaluable for response: N=6 (31,6%) achieved the primary endpoint, with all presenting stable disease. Median overall survival was 133 days (17 to 697) and median progression free survival was 43 days (14 to 210). Eight patients (42,1%) presented treatment-related G3-4 toxicities, with the most common being diarrhea. Six patients (31,6%) required dose-reduction of metformin because of diarrhea and one patient had paclitaxel dose-reduced due to febrile neutropenia. Conclusions: Despite the encouraging pre-clinical evidence of antitumor activity of metformin in PAC, the primary endpoint of disease control rate was not met in our trial. Besides, the treatment combination was poorly tolerated and should probably not be studied further. Clinical trial information: NCT01971034.
A Transgender Military Internist’s Perspective on Readiness for Treating Patients With Gender Dysphoria
Authors: Jamie L. Henry
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Predicting neurofibromatosis type 1 risk among children with isolated café-au-lait macules
Authors: Shay Ben-Shachar, Tom Dubov, Hagit Toledano-Alhadef, Jacob Mashiah, Eli Sprecher, Shlomi Constantini, Moshe Leshno, Ludwine M. Messiaen
Journal: Journal of the American Academy of Dermatology (2017)
CHANGES IN BODY FAT DISTRIBUTION IS ASSOCIATED WITH OXIDATIVE STRESS
Authors: Heval Mohamed Kelli, Frank Corrigan, Robert Heinl, Devinder Dhindsa, Muhammad Hammadah, Ayman Samman-Tahhan, Pratik Sandesara, Talal Alghamdi, Ibhar Al Mheid, Yi-An Ko, Thomas Ziegler, Laurence Sperling, Kenneth Brigham, Dean Jones, Viola Vaccarino, Greg Martin, Arshed Quyyumi
Journal: Journal of the American College of Cardiology (2017)
Preclusion of Secondary Phase of Irradiation Syndrome by Inoculation of Fetal Hematopoietic Tissue Following Lethal Total-Body X Irradiation
Authors: Delta E. Uphoff
Journal: JNCI Journal of the National Cancer Institute (1958)

Journal Article Preclusion of Secondary Phase of Irradiation Syndrome by Inoculation of Fetal Hematopoietic Tissue Following Lethal Total-Body X Irradiation Get access Delta E. Uphoff Delta E. Uphoff National Cancer Institute,3Bethesda, Maryland Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 20, Issue 3, March 1958, Pages 625–632, https://doi.org/10.1093/jnci/20.3.625 Published: 01 March 1958 Article history Received: 14 November 1957 Published: 01 March 1958
Mitoxantrone plus vinorelbine in pretreated patients with advanced breast cancer
Authors: A. Onyenadum, H. Gogas, C. Markopoulos, D. Bafaloukos, G. Aravantinos, A. Koutras, T. Makatsoris, D. Koukouras, N. Pavlidis, H. P. Kalofonos
Journal: Journal of Clinical Oncology (2005)

863 Background: Vinorelbine and mitoxantrone have both been demonstrated to have significant antitumor activity in patients with breast cancer. The aim of this study was to evaluate the efficacy and safety of the combination as second or third line treatment in patients with advanced breast cancer (ABC). Patients and Methods: Fifty-one previously treated patients with ABC were enrolled from October 2001 to May 2004 and 47 were eligible for treatment. Median age was 59 years (range 33–82) and ECOG performance status was <3. Distant sites of metastasis were as follows: liver 64%, bones 49%, lung 36%, lymph nodes 6%, skin 4%, brain 2% and other sites 6%. Locoregional lymph node metastasis was present in 17% of the patients. All patients received mitoxantrone 10mg/m2, D1 and vinorelbine 20mg/m2, D1+8 every 21 days for 6 cycles. A total of 204 cycles were delivered. The relative dose intensity of mitoxantrone and vinorelbine was 78% and 77%, respectively. Result: All eligible patients were analyzed for toxicity and for response. Two patients (4%) achieved complete response and twelve (25.5%) partial response. The objective overall response rate was 29.5% (95% confidence interval [CI] 17 - 45), 9 (19%) patients had stable disease, 17 (36%) had progressive disease and 7 (15%) were non-evaluable. After a median follow up of 18 months overall survival was 13 months (range 0.8 - 38+) and median time to disease progression was 5 months (range 1 - 32). Median time to treatment failure was 4 months (range 0.1 - 32). Toxicities (grade III-IV) were as follows: leukopenia 18 (38%), neutropenia 21 (45%), thrombocytopenia 1 (2%), anemia 4 (8.5%), alopecia 2 (4%) and constipation 1 (2%). Febrile neutropenia was recorded in one patient. No treatment related deaths were observed. Conclusion: The combination of mitoxantrone and vinorelbine is an effective and well tolerated regimen in pretreated patients with advanced breast cancer. No significant financial relationships to disclose.
IS THERE A ROLE FOR INVASIVE ELECTROPHYSIOLOGY STUDIES IN PATIENTS WITH CONDUCTION ABNORMALITIES FOLLOWING TRANSCATHETER AORTIC VALVE REPLACEMENT?
Authors: Ron Waksman, Toby Rogers, Mithun Devraj, Arie Steinvil, Edward Koifman, Michael Lipinski, Jiaxiang Gai, Rebecca Torguson, Petros Okubagzi, Lowell Satler, Augusto Pichard
Journal: Journal of the American College of Cardiology (2017)
A multicenter phase II trial with gemcitabine plus oxaliplatin as second line treatment in patients with advanced non-small cell lung cancer (NSCLC)
Authors: C. Kouroussis, K. Syrigos, A. Potamianou, N. Ziras, P. Ziotopoulos, J. Stergiou, P. Ginopoulos, E. Tselepatiotis, V. Biozionelou, V. Georgoulias
Journal: Journal of Clinical Oncology (2004)

7263 Background: Gemcitabine and Oxaliplatin have shown activity in NSCLC even in pretreated patients (pts). We conducted a phase II study to determine the activity of this combination as second line treatment in NSCLC. Methods: Patients were eligible if they had confirmed NSCLC, measurable or evaluable disease, performance status (ECOG) 0–2 and adequate hepatic, renal and bone marrow function. Gemcitabine dose was 1500mg/m2 (30 minute infusion) on days 1 and 8, and Oxaliplatin 130mg/m2 (2–6 hour infusion) on day 8. Cycles were administered every 3 weeks. Results: 24 pts were enrolled, 21 males and 3 females. Median age was 61.5 years (range 42–72); 83% had PS 0 or 1 and 17% PS 2; 12 pts had received 2 lines of treatment. All pts were evaluable for toxicity and 23 for response. Three pts achieved partial response (13%; 95% c.i 0.72%–26.81%) and 6 (26%) stable disease. The median time to progression was 3 months (range 1–12.7) and the median survival 5.6 months (range, 1–14). A total of 84 cycles were administered (median number/patient: 3) and the median dose administered was 85% for Gemcitabine and 81% for Oxaliplatin. No grade IV or febrile neutropenia occurred. Grade 3 neutropenia occurred in 4 (17%) pts, grade 3 anemia in 3 (12.5%) and grade 3 thrombocytopenia in 2 (8%). Non-hematological toxicity was mild and not clinically relevant. The only grade 3 non-hematological toxicity was neurotoxicity in 2 (8%) pts which was reversible with the discontinuation of treatment. Conclusions: The Gemcitabine plus Oxaliplatin is a well tolerated but marginally active regimen in pretreated pts with advanced NSCLC. No significant financial relationships to disclose.
Comparative Assessment of Different Clinically Utilized CD20 Directed Antibodies in Chronic Lymphocytic Leukemia (CLL) Cells Reveals Divergent NK-Cell, Monocyte and Macrophage Properties,
Authors: Sarwish Rafiq, Jonathan P. Butchar, Carolyn Cheney, Xiaokui Mo, David Jarjoura, Susheela Tridandapani, Natarajan Muthusamy, John C. Byrd
Journal: Blood (2011)
UNDERUTILIZATION OF HIGH INTENSITY STATINS IN A CONTEMPORARY HIGH RISK PCI POPULATION
Authors: Michela Faggioni, Usman Baber, Sonny Sayseng, Samantha Sartori, George Dangas, Choudhury Hasan, Annapoorna Kini, Jaya Chandrasekhar, Sabato Sorrentino, Birgit Vogel, Jason Kovacic, Nitin Barman, Pooja Vijay, Srushti Shah, Joseph Sweeny, Clayton Snyder, Serdar Farhan, Pedro Moreno, Srinivas Kesanakurthy, Vishal Kapur, Roxana Mehran, Samin Sharma
Journal: Journal of the American College of Cardiology (2017)
Public awareness of the HPV vaccine: A national population-based study.
Authors: Abigail Shrader, Linda Niccolai, Susan T Mayne, Daniel DiMaio, Anees B. Chagpar
Journal: Journal of Clinical Oncology (2013)

1574 Background: Human papilloma virus (HPV) is associated with a number of malignancies. While national guidelines exist for the use of HPV vaccines in men and women up to the age of 26, data are lacking regarding public awareness of these vaccines. Methods: The National Health Interview Survey is conducted annually by the CDC, and is designed to be representative of the US population. Questions regarding the HPV vaccine were fielded in 2010, and formed the basis of this analysis. Results: 9120 men and 10946 women between the ages of 18 and 64 were surveyed. More women than men had heard about the HPV vaccine (68.1% vs. 34.0%, p&lt;0.001), and young people (aged 18-26) were more likely to have heard about the vaccine than their older counterparts (54.3% vs. 50.5%, p=0.002). Factors associated with awareness of HPV vaccines amongst the younger cohort (eligible for the vaccine) are shown below. On multivariate analysis, race, insurance, and education were significant predictors of HPV vaccine awareness. Conclusions: While over half of young people aged 18-26 are aware of the HPV vaccine, racial/ethnic minorities, along with less educated and uninsured populations lag behind their majority counterparts in their awareness of the HPV vaccine. These data should be useful in directing public health educational programs. [Table: see text]
Phase I study of weekly docetaxel and topotecan in the treatment of advanced solid tumors
Authors: B. R. Tan, W. Read, K. Bergeron, P. M. Fracasso, R. Govindan
Journal: Journal of Clinical Oncology (2004)

7344 Background: Docetaxel has activity against a wide range of tumors and topotecan is a topoisomerase I inhibitor with activity in ovarian and small cell lung cancer. Docetaxel potentiates the cytotoxicity of topotecan in cell lines. Docetaxel given on a weekly schedule is associated with less myelosuppression compared to the standard 3-week schedule. Our prior study has shown that weekly topotecan is tolerable even at 10 mg/kg IV on days 1,8 and 15. (Tan, Proc ASCO 2002, 21:84b). We conducted a Phase I study of weekly docetaxel with weekly topotecan in patients with advanced malignancies to define the maximum tolerated doses(MTDs), and identify the dose-limiting toxicities (DLTs), for this regimen and schedule. Methods: A modified Fibonacchi dose escalation design was used with cohorts of 3 patients per dose level starting at dose level 1 until MTD is reached. At dose level 1, patients received docetaxel at 25 mg/m2 and topotecan at 4 mg/m2 intravenously on days 1, 8 and 15 of a 28-day-cycle. Results: A total of 13 patients (7 female/ 6 male) with median age of 56 were treated. Tumor types were as follows: NSCLC 9, small cell lung cancer, breast, adrenal, bladder ca- 1 each. Median number of prior therapy: 2 (range 1–6). Toxicity: As 2 out of 6 pts in cohort 1 developed DLTs (febrile neutropenia), subsequent patients were treated at dose level -1 with topotecan at 3 mg/m2 and docetaxel at 25 mg/m2. One of the 7 patients in dose -1 developed dose limiting thrombocytopenia. Other grade 3 toxicities observed include neutropenia (2) and thrombocytopenia (1). No significant non-hematologic toxicities were noted. Response: No objective responses were noted although 2 patients had stable disease. Conclusions: Febrile neutropenia and thrombocytopenia are dose limiting toxicities for weekly docetaxel and topotecan. The recommended Phase II doses are docetaxel at 25 mg/m2 and topotecan at 3 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Sanofi AstraZeneca; Sanofi Aventis, Inc.; GlaxoSmithKline; Eli Lilly
Efficacy and safety of administration of gemcitabine and docetaxel with radiation therapy in patients with high-grade soft tissue sarcoma
Authors: G. G. Raval, R. Govindarajan
Journal: Journal of Clinical Oncology (2009)

e21503 Background: Neo-adjuvant therapy of soft tissue sarcoma is not standardized. Anthracyclines (A) improve disease free and overall survival in high grade extremity soft tissue sarcomas measuring more than 5 cm. A and ifosfamide (I) therapy require inpatient administration and is associated with significant toxicities when administered in combination with RT. G in combination with D has been shown to prolong progression free and overall survival in patients with advanced or metastatic STS after progression on A and I, and in patients unable to receive the combination. The safety of administration of G with radiation is not known. We evaluated the safety of neo-adjuvant G and D in combination with RT in patients with STS. Methods: Retrospective analysis of subjects with high grade STS treated with RT and neo-adjuvant chemotherapy with G and D was conducted. G 600mg/m2 was administered on days 1 and 8 along with D 75 mg/m2 on day 8 for a total of 3 cycles. 2200 cGY RT was administered in 11 daily fractions between cycles 1 and 2 and between cycles 2 and 3. 72 hour gap was given between RT and chemotherapy. Chemotherapy was administered on outpatient basis. Efficacy was evaluated by the extent of tumor necrosis at the time of surgery. Safety was evaluated by the presence of complications following chemotherapy. Results: GD + R was administered to 12 patients in the neo-adjuvant setting. 11 of them were evaluable for response. 10 of the 11 patients had evidence of tumor necrosis at the time of surgery. 1 patient had poor response. 3 of 11 patients had neutropenia complicating neo-adjuvant chemotherapy. 4 patients required hospital admission post chemotherapy. 3 for neutopenic fever, and 1 for fever, chills and pneumonia without neutropenia. Conclusions: Gemcitabine and taxotere combination with radiation therapy can be administered safely on outpatient basis with minimal toxicity. Further safety and efficacy evaluation of this therapy will need to be confirmed in a prospective phase II study. No significant financial relationships to disclose.
MANAGEMENT OF MASSIVE HEMOPTYSIS IN POST CHEMOTHERAPY POST TRANSPLANT PATIENT WITH EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO)
Authors: Joseph Hellman, Ekamjeet Randhawa, Steffne Kunnirickal, Howard Eisen, Shelley Hankins, Farhan Hasni, Fischer Wade
Journal: Journal of the American College of Cardiology (2017)
SURVIVAL ANALYSIS FROM THALES STUDY, A LARGE NATION-WIDE REGISTRY ON PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONGENITAL HEART DISEASE
Authors: Mehmet Serdar Küçükoglu, Cihangir Kaymaz, Gul Sagin Saylam, Dursun Alehan, Serdar Kula, Atif Akcevin, Alpay Celiker, Sertac Cicek, Sadberk Lale Tokgozoglu
Journal: Journal of the American College of Cardiology (2017)
Effect of <i>RAS</i> on anti-EGFR monoclonal antibodies plus 5-FU infusion-based chemotherapy in first-line treatment of metastatic colorectal cancer: A meta-analysis.
Authors: Mingyi Zhou, Ping Yu, Kezuo Hou, Bo Jin, Xiujuan Qu, Yunpeng Liu, Yunpeng Liu, Jingdong Zhang
Journal: Journal of Clinical Oncology (2014)

e14623 Background: Efficacy of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (moAb) + 5-FU infusion based chemotherapy as first-line treatment of metastatic colorectal cancer (mCRC) were inconsistent. Not all patients with KRASexon 2 wild-type (-wt) response to this combination treatment. Methods: The MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, Cochrane databases, and ClinicalTrials.gov databases were independently reviewed from their dates of inception to December 2013. Results: Our meta-analysis suggested that, for KRAS exon 2-wt patients, this treatment reduced risk of progression and death and improved overall response rate (ORR) compared with chemotherapy alone (overall survival [OS]: hazard ratio [HR]: 0.88, p=0.008; progression-free survival [PFS]: HR 0.74, p<0.001; ORR: RR 1.34, p=0.003; 4 studies, 2,230 patients); adding anti-EGFR moAb reduced death risk compared with bevacizumab (Bev) (HR 0.73, p=0.001, 2 studies, 877 patients). Patients with KRAS exon 2-wt but other RAS mutations did not benefit from adding anti-EGFR moAb (OS: HR 0.73, p=0.534; PFS: HR 1.62, p=0.019; 2 studies, 116 patients). For RAS-wt patients, adding anti-EGFR moAb reduced death risk compared with Bev (HR 0.68, p=0.002, 2 studies, 512 patients). Subgroup analysis suggested that anti-EGFR moAb significantly improved PFS for male, liver metastasis-only, ECOG 0-1, and colon primary site groups. Anti-EGFR moAb increased controllable grade 3-4 toxicities including rash, diarrhea, and anemia. Conclusions: Anti-EGFR moAb + 5-FU infusion based chemotherapy as first-line treatment in RAS-wt mCRC patients significantly improved efficacy than KRAS exon 2-wt. Whereas KRAS exon 2-wt but other RAS mutations did not benefit from anti-EGFR moAb. Whether BRAF mutations is predictive marker to anti-EGFR moAb need more data to answer.
Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin lymphoma.
Authors: Cariad Chester, Serena Chang, John F. Kurland, Idit Sagiv-Barfi, Debra Czerwinski, Amanda Rajapaksa, Erin Waller, Mohith Sadaram, Lori Richards, Lewis J. Cohen, Christoph Matthias Ahlers, Maria Jure-Kunkel, Holden Maecker, Ronald Levy, Holbrook Edwin Kohrt
Journal: Journal of Clinical Oncology (2014)

3017 Background: Anti-CD137 antibody was shown in both murine cancer models and in a first-in-human, phase I trial (Sznol et al., 2008) to increase peripheral activated CD8 T cells and IFN-inducible genes, thereby facilitating a cytolytic, antitumor, Th1 response. A multiparametric immune pharmacodynamic assessment of the effects of anti-CD137 therapy has not been previously performed. Methods: We employed the novel technology of mass cytometry time of flight (CyTOF) to investigate the patient's global immune status prior to and during a phase 1 study (NCT01471210) of Urelumab, a fully human anti-CD137 antibody, administered once per 3-week cycle in patients with solid tumors and B-cell non-Hodgkin's lymphoma. Peripheral blood was obtained at 4 time points throughout treatment (baseline, 24-hrs after 1st dose of cycle 1, immediately before cycle 2, and post cycle 3 at response evaluation, C3R). PBMCs were isolated and stimulated for 4 hours with PMA/ionomycin. Immune cell characterization and function were analyzed in FlowJo and SPADE from mass cytometry results. Results: Preliminary findings from 4 patients show an increase in CD8 T cells up to 40.6% (SEM+/-13%) and NK cells up to 61.7% (SEM+/-20%) with a decrease in CD4 T cells up to 23.2% (SEM+/-6.5%) and regulatory CD4 T cells up to 17.8% (SEM+/-15%) comparing C3R to baseline. CyTOF cytokine analysis, revealed increases in GMCSF and IFN-gamma by C3R. CyTOF cytokine analysis, revealed increases in GMCSF and IFN-gamma by C3R. Conclusions: These preliminary data are consistent with anti-CD137 agonism and generate hypotheses of putative biomarkers of clinical activity now being investigated and to be reported from the ongoing clinical trial. Clinical trial information: NCT01471210.